Abstract | BACKGROUND: AIMS: METHODS: RESULTS: NMS in the steroid group healed within 10 days in 17 patients; median value of duration of illness of NMS in this group was 7 days (range 4-20). NMS in the placebo group healed within 10 days in five patients; in the remaining 15, it persisted for 12-27 days after the onset of NMS; median value of duration illness of NMS in this group was 18 days. Hyperthermia, rigidity, and consciousness improved within 10 days in many patients in the steroid group; these signs persisted more than 10 days in many patients in the placebo group. CONCLUSIONS:
Steroid pulse therapy is useful in NMS for reducing the illness duration and improving symptoms.
|
Authors | Y Sato, T Asoh, N Metoki, K Satoh |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 74
Issue 5
Pg. 574-6
(May 2003)
ISSN: 0022-3050 [Print] England |
PMID | 12700295
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Retracted Publication)
|
Chemical References |
- Antiparkinson Agents
- Neuroprotective Agents
- Methylprednisolone
|
Topics |
- Aged
- Antiparkinson Agents
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Male
- Methylprednisolone
(administration & dosage, therapeutic use)
- Neuroleptic Malignant Syndrome
(drug therapy, etiology)
- Neuroprotective Agents
(administration & dosage, therapeutic use)
- Parkinson Disease
(complications, drug therapy)
- Pulse Therapy, Drug
- Severity of Illness Index
- Time Factors
- Treatment Outcome
|